ClinicalTrialsFinder
RecruitingPhase 1NCT07450911

A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System

Sponsor

ReValve Solutions Inc.

Enrollment

20 participants

Start Date

Jan 27, 2026

Study Type

INTERVENTIONAL

Conditions

Mitral Regurgitation

Summary

An evaluation of the ReValve System for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Symptomatic MR (≥3+) due to ischemic and non-ischemic cardiomyopathy etiology determined by assessment of a qualifying transthoracic echocardiogram (TTE) obtained within 60 days and transesophageal echocardiogram (TEE) obtained within 90 days prior to subject registration, with MR severity based principally on the TTE study.
  • New York Heart Association (NYHA) Functional Class II, III or ambulatory IV.
  • Left Ventricular Ejection Fraction (LVEF) is ≥30% (within 90 days prior to subject registration, assessed by the site using any one of the following methods: echocardiography, contrast left ventriculography, gated blood pool scan or cardiac magnetic resonance imaging (MRI)).
  • Age greater than 18 years
  • Left Ventricular End Systolic Dimension (LVESD) is ≤ 65 mm assessed by site based on a transthoracic echocardiographic (TTE) obtained within 90 days prior to subject consent.

Exclusion Criteria8

  • Untreated clinically significant coronary artery disease requiring revascularization.
  • Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months.
  • Status 1 heart transplant or prior orthotopic heart transplantation
  • Cerebrovascular accident within 30 days prior to subject's consent
  • Pregnant or planning pregnancy within next 12 months.
  • Currently participating in an investigational drug or another device study.
  • Evidence of LV or left atrium (LA) thrombus, vegetation or mass
  • Known hypersensitivity or contraindication to procedural, post procedural medication (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or titanium.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEReValve System

Mitral Valve Replacement Device

Locations(3)

Healthycore

Tbilisi, Georgia

Tbilisi Heart and Vascular Center

Tbilisi, Georgia

Tiblisi Heart Center

Tbilisi, Georgia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07450911

Related Trials

Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

NCT0476112017 locations

Abbott Cephea Mitral Valve Disease Registry

NCT0706967322 locations

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

NCT0468819043 locations

Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock

NCT052981244 locations

A Clinical Study of GeminiOne TEER System for the Treatment of Severe, Symptomatic MR.

NCT070865341 location